Online inquiry

IVTScrip™ mRNA-Anti-alpha toxin&
lukE, ASN-1(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3284MR)

This product GTTS-WQ3284MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets alpha toxin&
lukE gene. The antibody can be applied in Staphylococcal infections research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq WP_000473596.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2828033; 59700577
UniProt ID P09616; A0A0H2WWN3
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-alpha toxin&
lukE, ASN-1(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ3284MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5717MR IVTScrip™ mRNA-Anti-CD3E&CEACAM5, CEA TCB(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CEA TCB
GTTS-WQ9610MR IVTScrip™ mRNA-Anti-VSIR, JNJ-61610588(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA JNJ-61610588
GTTS-WQ9328MR IVTScrip™ mRNA-Anti-TNFRSF18, INCAGN-01876(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA INCAGN-01876
GTTS-WQ1577MR IVTScrip™ mRNA-Anti-MSTN, ACE-083(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ACE-083
GTTS-WQ8413MR IVTScrip™ mRNA-Anti-HSP90, HSP90mab(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA HSP90mab
GTTS-WQ1748MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ADCT-301
GTTS-WQ10874MR IVTScrip™ mRNA-Anti-B4GALNT1, MAb-14.18(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MAb-14.18
GTTS-WQ4942MR IVTScrip™ mRNA-Anti-GP, c13C6-FR1-N(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA c13C6-FR1-N
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW